Welcome to our dedicated page for Cognex SEC filings (Ticker: CGNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cognex Corporation (CGNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this industrial machine vision issuer reports its financial and corporate information. Cognex is incorporated in Massachusetts and files under Commission File Number 001-34218, with its common stock listed on NASDAQ under the symbol CGNX.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, where Cognex discusses its machine vision business, risk factors, and financial statements. These filings are important for understanding trends in logistics and factory automation demand, as well as the company’s investment in AI-enabled vision products, as referenced in its public communications.
Investors will also find Form 8-K current reports that Cognex uses to announce material events. Recent 8-K filings include the release of quarterly financial results, dividend declarations, and an audit firm rotation in which the Audit Committee selected KPMG LLP as the independent registered public accounting firm for a future fiscal year, following Grant Thornton LLP. Such filings provide timely insight into corporate actions and governance decisions.
On this page, users can monitor real-time updates from EDGAR, including 8-Ks, 10-Qs, 10-Ks, and other forms that Cognex may file. Stock Titan’s tools offer AI-powered summaries that help explain the contents of lengthy filings, highlight key sections, and clarify technical language around accounting, risk disclosures, and strategic priorities. In addition, Form 4 insider transaction reports, when filed, can be accessed to review share transactions by Cognex officers, directors, or significant shareholders.
By using the CGNX filings page, investors and researchers can quickly move from raw SEC documents to clearer explanations of how Cognex presents its financial condition, machine vision strategy, and corporate developments in official filings.
Company CGNX reported insider sale activity via a Form 144 notice. The filing lists 61,900 common shares and an aggregate amount of $3,468,385.93 tied to 02/20/2026 on NASDAQ. The excerpt also shows 2,729 restricted shares dated 02/18/2026 and 59,171 shares from a stock option exercise dated 02/20/2026.
COGNEX CORP director Dianne M. Parrotte reported equity award activity involving restricted stock units and common shares. On February 18, 2026, she exercised or converted 8,324 restricted stock units into 8,324 shares of Cognex common stock at a stated price of $0.00 per share, increasing her direct common stock holdings to 30,518 shares.
The filing also lists updated direct holdings of several non-qualified stock options with rights to buy 7,500, 18,400 and 18,100 shares, and 2,913 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Cognex common stock and vests 100% on the first anniversary of the grant date, stated as February 18, 2025.
Cognex Corporation director and CEO & President Matthew Moschner reported equity compensation transactions. On February 17, 2026, he received 58,744 non-qualified stock options and 56,928 restricted stock units, both at a grant price of $0.00. The options vest in five approximately equal annual installments starting on the first anniversary of the grant date. The restricted stock units vest in stages of approximately 20%, 30%, and 50% over three years from the grant date. On February 18, 2026, 5,085 restricted stock units converted into 5,085 shares of common stock, increasing his directly held common stock to 13,447 shares. On the same date, 1,600 shares of common stock at $56.72 per share were withheld to cover tax obligations related to the vesting RSUs, reducing directly held common stock to 11,847 shares. Each restricted stock unit represents the right to receive one share of Cognex common stock.
Cognex Corporation senior vice president and chief financial officer Dennis Fehr reported several equity compensation movements. On February 17, 2026, he was granted 25,306 non-qualified stock options and 24,523 restricted stock units, both at a price of $0.00 per unit. The options vest in five approximately equal annual installments beginning one year after the grant date, while the restricted stock units vest 20%, 30%, and 50% over three years.
On February 18, 2026, 5,085 restricted stock units were converted into the same number of common shares, and 1,618 common shares were disposed of to satisfy tax withholding obligations at $56.72 per share. Following these transactions, Fehr directly owned 14,196 common shares and held 20,339 restricted stock units, along with substantial option holdings.
COGNEX CORP director Angelos Papadimitriou reported equity awards and conversions. On February 18, 2026, he exercised 8,324 restricted stock units at $0.0000 per share into the same number of common shares, bringing his direct common stock holdings to 17,835 shares. On February 17, 2026, he received a grant of 4,817 restricted stock units, which each represent a contingent right to one Cognex common share and vest 100% on the first anniversary of the grant date.
Cognex Corporation’s Chief Technology Officer, Joerg Kuechen, reported several equity-related transactions. On February 18, 2026, 4,056 restricted stock units were converted into an equal number of common shares at $0.00 per share, and 1,327 of those shares were disposed of at $56.72 per share to cover tax withholding obligations rather than through an open‑market sale. After these transactions, he directly held 2,729 shares of common stock. On February 17, 2026, he also received a direct grant of 8,759 new restricted stock units, which vest 100% on the second anniversary of the grant date. Additional non‑qualified stock options and restricted stock units are listed as existing holdings, reflecting his broader long‑term incentive position.
COGNEX CORP director John Tseng-Chung Lee reported equity compensation activity involving restricted stock units and common shares. On February 18, 2026, he exercised 8,324 restricted stock units for 8,324 shares of common stock at a price of $0.00 per share, bringing his direct common stock holdings to 21,907 shares.
On February 17, 2026, he received a grant of 4,817 restricted stock units, and a separate line shows 2,913 restricted stock units held directly after another transaction. Each restricted stock unit represents the right to receive one share of Cognex common stock, with footnotes indicating these awards vest 100% on the first anniversary of their respective grant dates.
COGNEX CORP director Marjorie Sennett reported equity award activity involving restricted stock units and common shares. On February 18, 2026, restricted stock units covering 8,324 shares were exercised for common stock at $0.0000 per share, leaving 23,023 common shares held directly.
On February 17, 2026, she received a grant of 4,817 restricted stock units, each representing a contingent right to one share of common stock. Footnotes state that certain restricted stock unit awards vest 100% on the first anniversary of their respective grant dates.
COGNEX CORP director Sachin Lawande reported equity awards and an RSU conversion. On February 18, 2026, 8,324 restricted stock units were exercised or converted into 8,324 shares of common stock at a stated price of $0.00 per share, leaving 25,518 common shares held directly.
On February 17, 2026, Lawande received a grant of 4,817 restricted stock units, each representing a contingent right to one share of Cognex common stock. Footnotes state that one RSU grant vests 100% on the first anniversary of the February 18, 2025 grant date, and another vests 100% on the first anniversary of the February 17, 2026 grant date.